Pathology is central to oncology. A pathologist examines tissue samples (biopsies) under a microscope to confirm cancer, determine its grade (how abnormal the cells look), and identify specific subtypes. This is the definitive confirmation before treatment begins.

Oncology involves multiple treatment modalities: surgery to remove tumors, radiotherapy to kill cancer cells with radiation, chemotherapy using drugs to kill fast-growing cells, targeted therapy that attacks specific molecules involved in cancer growth, and immunotherapy that harnesses the patient's own immune system. The choice depends on the cancer type, stage, and patient's health.

A critical aspect is 'financial toxicity', a term used when the cost of cancer treatment becomes a significant burden on patients and their families, sometimes leading to bankruptcy or foregoing necessary care. This is particularly relevant with expensive new drugs like Keytruda, where the price can be astronomical, as seen in the recent discussions about its affordability in India.

The concept of 'personalized medicine' is a major driver in modern oncology. Instead of a one-size-fits-all approach, treatment is tailored to the individual patient's genetic profile, the specific characteristics of their tumor, and their overall health. This maximizes effectiveness and minimizes side effects.

Clinical trials are the bedrock of progress in oncology. They are research studies involving patients that test new treatments, new ways of using existing treatments, or new ways to prevent or detect cancer. Without them, we wouldn't have many of the life-saving therapies available today.

A common exam trap is confusing different types of cancer treatments. Students often lump chemotherapy, immunotherapy, and targeted therapy together. It's vital to understand that while all aim to kill cancer cells, their mechanisms are distinct: chemo is a broad-spectrum poison, targeted therapy hits specific molecular 'switches', and immunotherapy 'wakes up' the immune system.

The development of drugs like Keytruda (pembrolizumab) highlights the ethical and economic challenges in oncology. While it's a breakthrough immunotherapy, its high cost, as reported, makes it inaccessible to many, leading to debates about dosage, pricing, and patient assistance programs. This tension between innovation and access is a recurring theme.

In India, the focus is increasingly on making advanced cancer treatments accessible. This includes exploring ways to reduce the cost of drugs, improving diagnostic capabilities in public health facilities, and strengthening cancer registries to better understand the disease burden. The government's role in regulating drug prices and ensuring availability through schemes like Ayushman Bharat is also crucial.

The examiner often tests the understanding of the *mechanism* of action for different cancer therapies. For instance, how does immunotherapy differ from chemotherapy? What is a checkpoint inhibitor? Understanding these differences is key for answering questions on medical advancements or public health challenges.

The recent debate around Keytruda's dosage in India, where oncologists suggest smaller, weight-based doses to reduce costs, illustrates a practical application of oncology principles. The manufacturer's resistance highlights the conflict between pharmaceutical business models and patient affordability, a recurring issue in public health policy.

Pathology is central to oncology. A pathologist examines tissue samples (biopsies) under a microscope to confirm cancer, determine its grade (how abnormal the cells look), and identify specific subtypes. This is the definitive confirmation before treatment begins.

Oncology involves multiple treatment modalities: surgery to remove tumors, radiotherapy to kill cancer cells with radiation, chemotherapy using drugs to kill fast-growing cells, targeted therapy that attacks specific molecules involved in cancer growth, and immunotherapy that harnesses the patient's own immune system. The choice depends on the cancer type, stage, and patient's health.

A critical aspect is 'financial toxicity', a term used when the cost of cancer treatment becomes a significant burden on patients and their families, sometimes leading to bankruptcy or foregoing necessary care. This is particularly relevant with expensive new drugs like Keytruda, where the price can be astronomical, as seen in the recent discussions about its affordability in India.

The concept of 'personalized medicine' is a major driver in modern oncology. Instead of a one-size-fits-all approach, treatment is tailored to the individual patient's genetic profile, the specific characteristics of their tumor, and their overall health. This maximizes effectiveness and minimizes side effects.

Clinical trials are the bedrock of progress in oncology. They are research studies involving patients that test new treatments, new ways of using existing treatments, or new ways to prevent or detect cancer. Without them, we wouldn't have many of the life-saving therapies available today.

A common exam trap is confusing different types of cancer treatments. Students often lump chemotherapy, immunotherapy, and targeted therapy together. It's vital to understand that while all aim to kill cancer cells, their mechanisms are distinct: chemo is a broad-spectrum poison, targeted therapy hits specific molecular 'switches', and immunotherapy 'wakes up' the immune system.

The development of drugs like Keytruda (pembrolizumab) highlights the ethical and economic challenges in oncology. While it's a breakthrough immunotherapy, its high cost, as reported, makes it inaccessible to many, leading to debates about dosage, pricing, and patient assistance programs. This tension between innovation and access is a recurring theme.

In India, the focus is increasingly on making advanced cancer treatments accessible. This includes exploring ways to reduce the cost of drugs, improving diagnostic capabilities in public health facilities, and strengthening cancer registries to better understand the disease burden. The government's role in regulating drug prices and ensuring availability through schemes like Ayushman Bharat is also crucial.

The examiner often tests the understanding of the *mechanism* of action for different cancer therapies. For instance, how does immunotherapy differ from chemotherapy? What is a checkpoint inhibitor? Understanding these differences is key for answering questions on medical advancements or public health challenges.

The recent debate around Keytruda's dosage in India, where oncologists suggest smaller, weight-based doses to reduce costs, illustrates a practical application of oncology principles. The manufacturer's resistance highlights the conflict between pharmaceutical business models and patient affordability, a recurring issue in public health policy.